In Vivo Bioimaging for Cancer Research Services
Inquiry
In oncology drug discovery, understanding how a candidate compound influences tumor behavior in its native microenvironment is as critical as knowing whether the tumor shrinks. Traditional endpoint measurements, such as caliper readings or post-mortem histology, provide static snapshots that often miss early signs of response, resistance, or metastasis. Alfa Cytology offers comprehensive in vivo bioimaging services designed to visualize, quantify, and track cancer biology in real time, delivering dynamic, multi-dimensional data that accelerate go/no-go decisions and deepen mechanistic insight.
Introduction to In Vivo Bioimaging
In vivo bioimaging is a suite of non-invasive technologies that enable longitudinal monitoring of tumor progression, molecular events, and host responses within living animals. Unlike conventional efficacy studies that rely on terminal endpoints, bioimaging allows the same cohort of animals to be followed from tumor initiation through treatment and beyond, capturing the temporal evolution of disease with high fidelity.
The core concept of in vivo imaging technology is to provide spatial, molecular, and systemic visibility into cancer biology.
Spatial visibility enables real-time localization of tumors and metastatic lesions within the living animal. Unlike caliper measurements limited to subcutaneous volumes, optical imaging (bioluminescence and fluorescence) can detect orthotopic, disseminated, and microscopic disease, including lesions as small as a few hundred cells that would otherwise remain invisible until necropsy.
Molecular visibility enables the visualization of specific biological processes at the cellular and subcellular level. Through genetically encoded reporters or targeted exogenous probes (e.g., enzyme-activatable fluorophores, nanoparticle-based sensors), researchers can monitor apoptosis, proliferation, angiogenesis, hypoxia, immune cell infiltration, and checkpoint molecule expression within the tumor microenvironment, all without sacrificing the animal.
Systemic visibility captures the host response to cancer beyond the tumor itself. Technologies such as magnetic resonance-based body composition analysis enable quantitative, non-anesthetized assessment of whole-body fat mass, lean mass, and fluid status, providing insight into cancer cachexia, metabolic reprogramming, and treatment-related toxicity, parameters entirely missed by traditional tumor-centric readouts.
These three dimensions transform in vivo imaging from a simple tumor-sizing tool into a platform for understanding cancer as a systemic disease, capturing tumor-host dynamics through repeated non-invasive measurements that static endpoints cannot provide.
Fig. 1 Molecular imaging techniques for real-time monitoring of immune cells and signaling molecules in the tumor microenvironment. (Wang X, et al.; 2025)
Our Services
Alfa Cytology offers a comprehensive suite of in vivo bioimaging services designed to visualize, quantify, and track cancer biology in real time, from tumor cell seeding to metastatic dissemination and systemic host response.
Our imaging platform integrates molecular probes, targeted nanoparticles, exosome-based tracers, and multi-modal fusion analytics to deliver high-dimensional data without sacrificing animals. Whether you are evaluating a novel drug candidate, characterizing a tumor model, or investigating tumor-stroma interactions, our services provide the spatial and temporal resolution needed for confident go/no-go decisions.
Real-Time In Vivo Fluorescence Imaging
Utilizes multi-color fluorescence (GFP, RFP, NIR) to track tumor cell proliferation, migration, and metastasis in real time. Enables longitudinal monitoring of therapeutic response and resistance in the same animal cohort.
Tumor-Selective Imaging with Carbon Quantum Dots
Employs functionalized carbon quantum dots (CQDs) for tumor-specific imaging with low background and high signal-to-noise ratio. Detects microscopic lesions and minimal residual disease with excellent biocompatibility.
Tumor Exosome-Based Imaging
Leverages natural tumor-targeting exosomes to trace biodistribution, organotropism, and pre-metastatic niche formation. Supports drug discovery, exosome-based delivery, and ascites/effusion-derived applications.
EchoMRI Body Composition Analysis
Uses magnetic resonance technology to non-invasively quantify fat mass, lean mass, and fluid status in tumor-bearing animals. Enables longitudinal assessment of cachexia and metabolic reprogramming without anesthesia.
Spatially aligns fluorescence signals, structural images, and body composition data. Provides 3D visualization, co-localization analysis, and multi-parametric reports for integrated data interpretation.
Applications of Our Imaging Services
- PD/PK study: Correlate drug exposure with imaging endpoints
- Acute toxicology: Detect organ toxicity via body composition imaging
- Metastasis models: Track metastasis in vivo
- Imaging biomarkers: Identify non-invasive response signatures
Oncology Drug Discovery & Screening
- Rapid screening: 3–5 mice/group, 2–3 doses, results in 1–4 weeks
- Mechanism studies: Assess proliferation, apoptosis, and angiogenesis
- Combination optimization: Evaluate multi-agent synergy
Personalized Precision Oncology
- PDOX-guided therapy: Test patient-specific drug responses
- Response prediction: Correlate baseline imaging with outcomes
- Microtumor intervention: Image-guided targeting of microscopic tumors
- Immune cell tracking: Monitor T cell, NK cell, macrophage infiltration
- Checkpoint mapping: Visualize PD-L1, CTLA-4 expression
- Immunotherapy response: Differentiate pseudo-progression from true progression
Workflow of Our Service
Alfa Cytology offers flexible in vivo bioimaging packages customized to your specific program needs—whether you require single-modality tumor tracking, multi-parametric TME characterization, or full-service longitudinal studies with metabolic assessment. Our team of imaging scientists is ready to assist with study design, probe selection, and data interpretation. If you seek further exploration of in vivo bioimaging services for your cancer drug candidates, please feel free to contact us.
Reference
- Wang X, et al. Current status and future prospects of molecular imaging in targeting the tumor immune microenvironment. Front Immunol. 2025;16:1518555.
For research use only.
Related Services
